Abstract
FoxO1, one of the most widely expressed sub-families of the winged helix forkhead factors, is biologically ‘omni-functional’ owing to its far-flung roles in metabolism, cell cycle, tissue differentiation and development and oxidative stress response. The knowledge of involvement of FoxO1 in metabolic disorders has long been there, but the potential target remained underutilized due to unavailability of specific and potent inhibitors. The review provides an insight into the role of FoxO1 in orchestrating metabolic diseases’ pathogenesis (including diabetes, its secondary complications and obesity) and compiles the literature on FoxO1 inhibitors. The emergence of various natural molecules and synthesized small molecules like AS1842856 as FoxO1 inhibitors urges us to think further and decide the future course of drug development for the management of metabolic disorders.
Keywords: FoxO1, metabolic disorders, diabetes, diabetic complications, obesity, FoxO1 inhibitors, AS1842856.
Current Diabetes Reviews
Title:FoxO1 Inhibitors: The Future Medicine for Metabolic Disorders?
Volume: 12 Issue: 3
Author(s): Anuradha Pandey, Goru Santosh Kumar, Almesh Kadakol, Vajir Malek and Anil Bhanudas Gaikwad
Affiliation:
Keywords: FoxO1, metabolic disorders, diabetes, diabetic complications, obesity, FoxO1 inhibitors, AS1842856.
Abstract: FoxO1, one of the most widely expressed sub-families of the winged helix forkhead factors, is biologically ‘omni-functional’ owing to its far-flung roles in metabolism, cell cycle, tissue differentiation and development and oxidative stress response. The knowledge of involvement of FoxO1 in metabolic disorders has long been there, but the potential target remained underutilized due to unavailability of specific and potent inhibitors. The review provides an insight into the role of FoxO1 in orchestrating metabolic diseases’ pathogenesis (including diabetes, its secondary complications and obesity) and compiles the literature on FoxO1 inhibitors. The emergence of various natural molecules and synthesized small molecules like AS1842856 as FoxO1 inhibitors urges us to think further and decide the future course of drug development for the management of metabolic disorders.
Export Options
About this article
Cite this article as:
Pandey Anuradha, Kumar Santosh Goru, Kadakol Almesh, Malek Vajir and Gaikwad Bhanudas Anil, FoxO1 Inhibitors: The Future Medicine for Metabolic Disorders?, Current Diabetes Reviews 2016; 12 (3) . https://dx.doi.org/10.2174/1573399811666150804104858
DOI https://dx.doi.org/10.2174/1573399811666150804104858 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Protein O-GlcNAcylation: A Critical Regulator of the Cellular Response to Stress
Current Signal Transduction Therapy Insulin Therapy in Cardiac Surgery
Current Diabetes Reviews Pro- and Anti-Arrhythmic Effects of Anti-Inflammatory Drugs
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Relationship Between Cigarette Smoking and Other Coronary Risk Factors in Atherosclerosis: Risk of Cardiovascular Disease and Preventive Measures
Current Pharmaceutical Design The Heart in Sepsis: From Basic Mechanisms to Clinical Management
Current Vascular Pharmacology A Review of Sirt1 and Sirt1 Modulators in Cardiovascular and Metabolic Diseases
Recent Patents on Cardiovascular Drug Discovery Sleep-Disordered Breathing and Cardiovascular Disease: Exploring Pathophysiology and Existing Data
Current Respiratory Medicine Reviews Cardiovascular Magnetic Resonance T2-weighted Imaging of Myocardial Edema in Acute Myocardial Infarction
Recent Patents on Cardiovascular Drug Discovery Amino Acid and Polyamine Membrane Transporters in Trypanosoma cruzi: Biological Function and Evaluation as Drug Targets
Current Medicinal Chemistry Evaluation of the Antioxidant and Antidiabetic Potential of the Poly Herbal Formulation: Identification of Bioactive Factors
Cardiovascular & Hematological Agents in Medicinal Chemistry Endothelial Dysfunction in Heart Failure: Mechanisms and Therapeutic Approaches
Current Vascular Pharmacology Oxidative-Nitrosative Stress as a Contributing Factor to Cardiovascular Disease in Subjects with Diabetes
Current Vascular Pharmacology Hypocholesterolemia
Current Vascular Pharmacology Glucocorticoid Analogues: Potential Therapeutic Alternatives for Treating Inflammatory Muscle Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Calcium Channel Blockers in Obesity-Related Hypertension
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Two fACEs of the Tissue Renin-Angiotensin Systems: Implication in Cardiovascular Diseases
Current Pharmaceutical Design Sacubitril/Valsartan: A New Dawn has Begun! A Revisited Review
Current Cardiology Reviews Beta-2 Agonists in Asthma: Medicine or Murderer?
Current Respiratory Medicine Reviews Protective Effects of Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) Against Apoptosis
Current Pharmaceutical Design Acetylome Regulation by Sirtuins in the Brain: From Normal Physiology to Aging and Pathology
Current Pharmaceutical Design